Energenesis Biomedical Co Ltd
TWSE:6657
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| TW |
E
|
Energenesis Biomedical Co Ltd
TWSE:6657
|
4.2B TWD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
412B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
199B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.4B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
84.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
72.7B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.1B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -22 082.4% |
| 30th Percentile | 1% |
| Median | 5.3% |
| 70th Percentile | 11.1% |
| Max | 1 580% |
Other Profitability Ratios
Energenesis Biomedical Co Ltd
Glance View
Energenesis Biomedical Co., Ltd. engages in the development of new drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-08-08. The firm's main product projects include experimental service analysis and reagent sales. The firm's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Energenesis Biomedical Co Ltd is -3 267.7%, which is above its 3-year median of -3 498.6%.
Over the last 3 years, Energenesis Biomedical Co Ltd’s Net Margin has increased from -3 614.4% to -3 267.7%. During this period, it reached a low of -4 017.8% on Jun 30, 2023 and a high of -2 940.2% on Jun 30, 2024.
